Zobrazeno 1 - 10
of 25
pro vyhledávání: '"B. L. Samuels"'
Autor:
S. M. Griffies, A. Gnanadesikan, K. W. Dixon, J. P. Dunne, R. Gerdes, M. J. Harrison, A. Rosati, J. L. Russell, B. L. Samuels, M. J. Spelman, M. Winton, R. Zhang
Publikováno v:
Ocean Science, Vol 1, Iss 1, Pp 45-79 (2005)
This paper summarizes the formulation of the ocean component to the Geophysical Fluid Dynamics Laboratory's (GFDL) climate model used for the 4th IPCC Assessment (AR4) of global climate change. In particular, it reviews the numerical schemes and phys
Externí odkaz:
https://doaj.org/article/a329161b16824217abe77a7fc1aa2d7c
Publikováno v:
Annals of Oncology. 5:S1-S3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::90b9945a9de5e7f0d32dfe12997021a5
https://doi.org/10.1093/annonc/5.suppl_2.s1-b
https://doi.org/10.1093/annonc/5.suppl_2.s1-b
Autor:
B L, Samuels, D R, Hollis, G L, Rosner, D L, Trump, C L, Shapiro, N J, Vogelzang, R L, Schilsky
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 3(11)
Multidrug resistance mediated by P-glycoprotein may be an important cause of chemotherapy failure. Renal cell carcinoma is a disease known to demonstrate a high degree of intrinsic chemotherapy drug resistance, and this has been shown to be related t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a11959951b3437b13dafa649fd2ab59c
https://pubmed.ncbi.nlm.nih.gov/9815587
https://pubmed.ncbi.nlm.nih.gov/9815587
Autor:
B L, Samuels, J E, Herndon, D C, Harmon, R, Carey, J, Aisner, J M, Corson, Y, Suzuki, M R, Green, N J, Vogelzang
Publikováno v:
Cancer. 82(8)
In a prior Cancer and Leukemia Group B (CALGB) Phase II trial of patients with advanced, previously untreated mesothelioma, dihydro-5-azacytidine (DHAC) demonstrated a 17% response rate, including 1 complete response, with only mild myelosuppression.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::02378e76fb7db44806434225a6a0f143
https://pubmed.ncbi.nlm.nih.gov/9554537
https://pubmed.ncbi.nlm.nih.gov/9554537
Publikováno v:
Seminars in oncology. 25(1 Suppl 2)
Ifosfamide and vinorelbine have demonstrated single-agent activity against advanced non-small cell lung cancer. The dose-limiting toxicity of each agent is myelosuppression. Several trials have studied this combination to determine its toxicity and e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::03efdb108347d83ae3b73c2e392321ed
https://pubmed.ncbi.nlm.nih.gov/9535205
https://pubmed.ncbi.nlm.nih.gov/9535205
Autor:
P C, Hoffman, G A, Masters, L C, Drinkard, S A, Krauss, B L, Samuels, H M, Golomb, E E, Vokes
Publikováno v:
Seminars in oncology. 23(3 Suppl 6)
Two studies were performed to determine the maximum tolerated dose (MTD) of paclitaxel and vinorelbine, respectively, in combination with a fixed dose of ifosfamide in previously untreated patients with stage IIIB or IV non-small cell lung cancer. Re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3df8e6d3cdd7c7f39a904ef89e96b42e
https://pubmed.ncbi.nlm.nih.gov/8677441
https://pubmed.ncbi.nlm.nih.gov/8677441
Publikováno v:
Seminars in oncology. 23(2 Suppl 5)
Vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Medicament, Paris, France), a semisynthetic vinca alkaloid, and ifosfamide have each shown activity as a single agent and in various combination-chemotherapy regi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c920d8710956f0cea0296c652a8c340c
https://pubmed.ncbi.nlm.nih.gov/8610230
https://pubmed.ncbi.nlm.nih.gov/8610230
Publikováno v:
Biochemistry and molecular biology international. 38(2)
Selenocysteine tRNA[Ser]Sec isoacceptors contain the modified nucleotide i6A immediately 3' to the anticodon. Because synthesis of i6A is expected to be inhibited by lovastatin, the status of tRNA[Ser]Sec isoacceptors was examined in human breast car
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ee2a1a4ff7714ca5e1725498b315dbfc
https://pubmed.ncbi.nlm.nih.gov/8850530
https://pubmed.ncbi.nlm.nih.gov/8850530
Autor:
G A, Masters, L C, Drinkard, P C, Hoffman, N, Lane, S, Watson, B L, Samuels, J D, Bitran, H M, Golomb, E E, Vokes
Publikováno v:
The cancer journal from Scientific American. 1(4)
The combination of cisplatin, 5-fluorouracil, and leucovorin (PFL) has been reported to have a 29% response rate in advanced non-small cell lung cancer. Vinorelbine, a semi-synthetic vinca alkaloid, has also been reported to have single-agent activit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2e18808b681831d7ca64784c4c5cf940
https://pubmed.ncbi.nlm.nih.gov/9166490
https://pubmed.ncbi.nlm.nih.gov/9166490
Autor:
P C, Hoffman, S A, Krauss, L C, Drinkard, G A, Masters, B L, Samuels, J D, Bitran, H M, Golomb, S, Watson, E E, Vokes
Publikováno v:
Seminars in oncology. 22(4 Suppl 9)
Both paclitaxel and ifosfamide have significant single-agent activity in non-small cell lung cancer. We designed a phase I study combining escalating doses of paclitaxel, administered by 24-hour infusion, with ifosfamide given at a dose of 1.6 g/m2 d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::844f1587a4dbe7f26027b1f1594da63e
https://pubmed.ncbi.nlm.nih.gov/7544026
https://pubmed.ncbi.nlm.nih.gov/7544026